Universal Vision Biotechnology Co

Universal Vision Biotechnology Co Current Assets

The Current Assets of Universal Vision Biotechnology Co (3218.TWO) as of Oct 22, 2026 is 374.73 M TWD. In the previous year, Current Assets was 924.38 M TWD — a change of -59.46% (lower).

Current Assets

374.73 MTWD

YoY

-59.46%

Last updated:

Current Assets of Universal Vision Biotechnology Co is 2025 374.73 M TWD. Current Assets of Universal Vision Biotechnology Co was 2024 924.38 M TWD. It decreases by -59.46% lower compared to the previous year.

The Universal Vision Biotechnology Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
456.43 M TWD
Jan 1, 2019
1.26 B TWD
Jan 1, 2020
1.64 B TWD
Jan 1, 2021
1.78 B TWD
Jan 1, 2022
2.16 B TWD
Jan 1, 2023
2.58 B TWD
Jan 1, 2024
924.38 M TWD
Jan 1, 2025
374.73 M TWD
The Universal Vision Biotechnology Co Current Assets history
YEARCurrent AssetsYoY
374.73 MTWD-59.46%
924.38 MTWD-64.17%
2.58 BTWD+19.50%
2.16 BTWD+21.35%
1.78 BTWD+8.35%
1.64 BTWD+29.96%
1.26 BTWD+176.82%
456.43 MTWD+5.94%
430.82 MTWD+0.47%
428.79 MTWD-9.74%
475.05 MTWD+16.36%
408.24 MTWD+8.35%
376.77 MTWD-1.72%
383.38 MTWD+1.31%
378.42 MTWD+9.96%
344.13 MTWD-2.69%
353.63 MTWD+13.45%
311.72 MTWD+36.23%
228.82 MTWD+24.13%
184.33 MTWD-8.75%
202.00 MTWD+158.54%
78.13 MTWD+158.38%
30.24 MTWD-78.54%
140.89 MTWD+320.16%
33.53 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Universal Vision Biotechnology Co Stock analysis

What does Universal Vision Biotechnology Co do? Universal Vision Biotechnology Co., Ltd. generates revenue through the sale of optical instruments, glasses, contact lenses, and glass ornaments. The company also provides laser vision correction equipment and services, trades medical drugs, and offers leasing of medical facilities, clinic operation planning, and medical cosmetology services. Its primary market is Taiwan, where it serves customers seeking vision correction solutions and medical aesthetic treatments. The firm's product portfolio includes optical instruments, glasses, contact lenses, and glass ornaments, alongside medical drug trading. Services such as laser vision correction, medical facility leasing, clinic operation planning, and medical cosmetology are key revenue drivers. Taiwan-based customers, including individuals requiring vision care and clinics needing operational support, form the core market segment. Revenue streams are derived from the direct sale of optical products, medical drug trading, and service-based offerings like laser vision correction and medical cosmetology. The company operates exclusively within Taiwan, focusing on both consumer and clinic-level clients for its comprehensive vision and medical aesthetics solutions. Universal Vision Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Universal Vision Biotechnology Co stock

Current Assets of Universal Vision Biotechnology Co is 374.73 M TWD in 2025.

Current Assets of Universal Vision Biotechnology Co changed from 924.38 M TWD to 374.73 M TWD, representing a -59.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Universal Vision Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Universal Vision Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Universal Vision Biotechnology Co

All Key Metrics — Universal Vision Biotechnology Co